Passage Bio Inc. (PASG): Price and Financial Metrics
GET POWR RATINGS... FREE!
PASG Stock Price Chart Interactive Chart >
PASG Price/Volume Stats
|Current price||$1.46||52-week high||$5.33|
|Prev. close||$1.43||52-week low||$1.04|
|Day high||$1.50||Avg. volume||159,610|
|50-day MA||$1.38||Dividend yield||N/A|
|200-day MA||$1.77||Market Cap||79.65M|
Passage Bio Inc. (PASG) Company Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Most Popular Stories View All
PASG Latest News Stream
|Loading, please wait...|
PASG Latest Social Stream
View Full PASG Social Stream
Latest PASG News From Around the Web
Below are the latest news stories about PASSAGE BIO INC that investors may wish to consider to help them evaluate PASG as an investment opportunity.
PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 7600 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price
After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain
To get a sense of who is truly in control of Passage Bio, Inc. ( NASDAQ:PASG ), it is important to understand the...
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!
Passage Bio Inc (NASDAQ: PASG) announced new interim safety, biomarker, and clinical development results from cohorts 1-3 in the Imagine-1 Phase 1/2 study of AAVhu68 gene therapy PBGM01 for GM1 Gangliosidosis (GM1). GM1 is a rare, fatal lysosomal storage disease in which mutations in the GLB1 gene result in the deficient activity of the enzyme beta-galactosidase (β-Gal), an enzyme that helps break down fats and sugars. PBGM01 administration resulted in dose-dependent increases in CSF β-Gal activ
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in dose-dependent increases in CSF β-Gal activity and decreases in CSF GM1 gangliosidesPBGM01 administration resulted in a meaningful improvement across developmental areas in a subset of patients, as assessed by investigators and caretakersCompleted dosing of all patients in dose-ascending portion of study; initia
PASG Price Returns